Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications work partly by slowing how fast food leaves your stomach, which reduces hunger and calorie intake. This intentional slowing of gastric emptying has raised questions about whether GLP-1 therapy causes gastroparesis, a serious condition where the stomach cannot empty properly. PlexusDx clarifies what the clinical evidence actually shows.
How GLP-1 Medications Affect Stomach Function
GLP-1 receptor agonists like semaglutide and tirzepatide activate receptors on stomach muscle cells, which delays the rate at which the stomach contracts and pushes food into the small intestine. This pharmacologic effect is intentional and contributes to the appetite suppression and weight loss benefits patients experience. The delay typically ranges from 10 to 20 minutes longer than baseline, which is mild and reversible when medication is stopped.
This gastric slowdown is not the same as gastroparesis, which is a medical disorder where the stomach loses the ability to contract effectively at all. In gastroparesis, food may sit in the stomach for hours, causing severe bloating, nausea, vomiting, and malnutrition. GLP-1-induced gastric slowing is a temporary, dose-dependent effect that most patients tolerate without problems.
Gastroparesis Risk and GLP-1 Clinical Trial Data
Major clinical trials of semaglutide (SUSTAIN series) and tirzepatide (SURPASS series) monitored patients for gastroparesis-related symptoms across thousands of participants over 52 to 104 weeks. Rates of severe nausea or vomiting were reported in 3 to 8 percent of GLP-1 users, but confirmed gastroparesis diagnoses requiring gastric emptying studies were extremely rare. No significant increase in gastroparesis diagnosis was detected compared to placebo groups in any pivotal trial.
Post-market surveillance and real-world data from millions of GLP-1 prescriptions have not identified a widespread gastroparesis epidemic. Patients with pre-existing gastric motility disorders or a personal history of gastroparesis do carry higher risk and should discuss GLP-1 candidacy with their physician before starting treatment. PlexusDx coordinates care with your doctor to identify any contraindications during the onboarding process.
Distinguishing GLP-1 Side Effects From True Gastroparesis
Common GLP-1 side effects—nausea, mild stomach discomfort, reduced appetite, and slower digestion—typically appear within the first 1 to 2 weeks of starting therapy and tend to fade as the body adapts. These effects are usually mild to moderate and do not require stopping the medication. Patients who continue treatment often find that symptoms resolve within 4 to 6 weeks without intervention.
Warning signs of gastroparesis include persistent severe nausea or vomiting that prevents eating or drinking, unexplained weight loss beyond the intended effect, severe abdominal bloating or pain, and food regurgitation. If any of these symptoms develop or worsen after weeks on GLP-1 therapy, a gastroenterologist can perform gastric emptying scintigraphy to confirm or rule out gastroparesis. Early reporting to your PlexusDx care team or primary doctor ensures proper evaluation.
Reducing GLP-1 Side Effects and Supporting Digestive Health
Starting at the lowest effective dose and increasing gradually allows your stomach to adjust to GLP-1's effects over weeks rather than days. PlexusDx Semaglutide Injection starts at $149 per month with flat pricing regardless of dose—meaning your dose may go up, but your price won't. Eating smaller, more frequent meals and staying hydrated can reduce early nausea. Avoiding high-fat or high-fiber foods during the first few weeks may also help tolerance.
PlexusDx offers personalized treatment plans based on your clinical profile and, if desired, the Precision Peptide Genetic Test ($99 add-on after your first month). This genetic panel examines variants in GLP1R, GIPR, FTO, and MC4R pathways to help predict your individual response to GLP-1 therapy and refine your treatment plan. Patients with data-driven insight into their peptide biology are better equipped to anticipate side effects and optimize results.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can GLP-1 injections like semaglutide actually cause gastroparesis?
GLP-1 medications slow stomach emptying intentionally, but clinical trials and post-market data show that confirmed gastroparesis diagnoses are extremely rare. True gastroparesis—where the stomach cannot contract at all—has not been proven to result directly from GLP-1 use. Transient nausea and mild gastric slowing are expected side effects that usually resolve within weeks.
What percentage of GLP-1 patients develop gastroparesis symptoms?
Nausea or vomiting occurs in 3 to 8 percent of GLP-1 trial participants, but the vast majority resolve without discontinuing therapy. Diagnosis of actual gastroparesis requiring clinical intervention remains rare across millions of GLP-1 users globally. Starting at a low dose and titrating slowly minimizes the risk of severe gastrointestinal symptoms.
How much does semaglutide cost at PlexusDx?
PlexusDx Compounded Semaglutide Injection starts at $149 per month with flat monthly pricing across all dose levels—your dose may go up, but your price won't. The medication is compounded by licensed 503A pharmacies, requires no insurance, and is HSA/FSA eligible. PlexusDx serves all 50 states with no membership fees.
Should people with a history of stomach problems avoid GLP-1?
Patients with pre-existing gastroparesis, gastric ulcers, or severe reflux disease should discuss GLP-1 candidacy carefully with their physician. These conditions increase risk for GLP-1-related complications, but are not automatic contraindications. PlexusDx care coordination ensures your medical history is reviewed before starting any medication.
How does the PlexusDx Precision Peptide Genetic Test help with GLP-1 side effects?
PlexusDx's genetic panel examines GLP1R, GIPR, FTO, and MC4R variants that influence your individual peptide-hormone response and predicted tolerability of GLP-1 therapy. Understanding your genetic pathway predispositions helps your care team anticipate side effects, optimize dosing, and personalize your treatment plan. The test costs $99 and is available after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Exploring Weight Loss Medications: Are There Other Drugs Besides Ozempic?
Is All Semaglutide Compounded? Understanding Your Options for Weight Loss